Enanta Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
ENTA
CUSIP
29251M106
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 29251M106 since 12/18/2024, newest first.

Filer % of Class Filed
Deep Track Capital, LP 13G/A Amendment 2
4.97% 8/14/2026
Event 6/30/2026
Farallon Capital Management, L.L.C. 13G/A Amendment 8
8.3% 8/14/2026
Event 6/30/2026
Vanguard Group Inc 13G/A Amendment 6 0% 3/26/2026
Event 3/13/2026
Deep Track Capital, LP 13G/A Amendment 1
6.8% 2/13/2026
Event 12/31/2025
Farallon Capital Partners, L.P. 13G/A Amendment 7
9.8% 2/5/2026
Event 12/31/2025
Integrated Core Strategies (US) LLC 13G/A Amendment 2
2.3% 1/20/2026
Event 12/31/2025
Integrated Core Strategies (US) LLC 13G/A Amendment 1
4.1% 11/13/2025
Event 9/30/2025
Janus Henderson Group PLC 13G
12.1% 11/7/2025
Event 10/31/2025
Deep Track Capital, LP 13G
5.3% 10/9/2025
Event 10/2/2025
BlackRock, Inc. 13G/A Amendment 5 7.8% 4/17/2025
Event 3/31/2025
Luly Jay R. 13D/A Amendment 3 7.7% 2/14/2025
Event 2/12/2025
Farallon Capital Partners, L.P. 13G/A Amendment 6
9.9% 2/11/2025
Event 12/31/2024
Integrated Core Strategies (US) LLC 13G
6.5% 1/22/2025
Event 1/14/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 3.22 k $42.4 k
2026 Q2 126 27.3 M $398 M
2026 Q1 137 26.8 M $338 M
2025 Q4 135 26.4 M $416 M
2025 Q3 130 19.1 M $229 M
2025 Q2 112 18.7 M $142 M
2025 Q1 113 18.6 M $103 M
2024 Q4 113 21.4 M $127 M
2024 Q3 117 21.5 M $222 M
2024 Q2 107 23.7 M $308 M
2024 Q1 115 26.6 M $465 M
2023 Q4 113 21.5 M $203 M
2023 Q3 138 20.2 M $225 M
2023 Q2 138 20.2 M $438 M
2023 Q1 152 19.9 M $806 M
2022 Q4 155 20.8 M $966 M
2022 Q3 168 19.7 M $1.02 B
2022 Q2 160 20.2 M $956 M
2022 Q1 179 19.7 M $1.40 B
2021 Q4 193 18.8 M $1.41 B
2021 Q3 152 19.4 M $1.10 B
2021 Q2 159 18.9 M $831 M
2021 Q1 158 19.4 M $957 M
2020 Q4 161 20.0 M $843 M
2020 Q3 178 18.9 M $863 M
2020 Q2 189 18.3 M $918 M
2020 Q1 167 18.1 M $930 M
2019 Q4 182 18.6 M $1.15 B
2019 Q3 188 17.9 M $1.08 B
2019 Q2 208 17.8 M $1.50 B
2019 Q1 210 18.2 M $1.74 B
2018 Q4 192 17.0 M $1.21 B
2018 Q3 212 16.9 M $1.45 B
2018 Q2 204 15.1 M $1.75 B
2018 Q1 189 14.8 M $1.20 B
2017 Q4 150 14.0 M $824 M
2017 Q3 131 12.8 M $598 M
2017 Q2 127 12.6 M $454 M
2017 Q1 133 12.9 M $397 M
2016 Q4 152 13.4 M $448 M
2016 Q3 139 13.1 M $349 M
2016 Q2 134 13.4 M $296 M
2016 Q1 157 14.2 M $418 M
2015 Q4 143 14.6 M $483 M
2015 Q3 148 16.0 M $593 M
2015 Q2 135 13.8 M $622 M
2015 Q1 120 12.4 M $380 M
2014 Q4 129 10.8 M $552 M
2014 Q3 117 11.3 M $445 M
2014 Q2 102 9.76 M $420 M
2014 Q1 81 8.44 M $337 M